Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Avalglucosidase Alfa French Post-Trial Adgang for deltagere med Pompes sygdom (PTA Avalglucosidase)

4. september 2026 opdateret af: Genzyme, a Sanofi Company

En fransk multicenter fase 4 Open Label forlængelsesundersøgelse af langsigtet sikkerhed og effektivitet hos patienter med Pompes sygdom, som tidligere har deltaget i Avalglucosidase-udviklingsstudier i Frankrig

Dette langsigtede åbne sikkerheds- og effektivitetsstudie er beregnet til at følge op og give post-studie adgang til enzymerstatningsterapi (ERT) med avalglucosidase alfa til patienter med Pompes sygdom i Frankrig, som har gennemført undersøgelse EFC14028, LTS13769 eller ACT14132 , fra markedstilladelse til refusion af avalglucosidase alfa i Frankrig eller indtil maj 2023, alt efter hvad der kommer først.

- Studiebesøgsfrekvens: hver 2. uge

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Behandlingsvarighed ca. 16 måneder

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

17

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Frankrig
      • Bordeaux, Frankrig, 33000
        • Investigational Site Number : 2500004
      • Brest, Frankrig, 29609
        • Investigational Site Number : 2500005
      • Clermont-Ferrand, Frankrig, 63000
        • Investigational Site Number : 2500008
      • Lille, Frankrig, 59037
        • Investigational Site Number : 2500009
      • Lyon, Frankrig, 69003
        • Investigational Site Number : 2500003
      • Marseille, Frankrig, 13385
        • Investigational Site Number : 2500001
      • Nantes, Frankrig, 44093
        • Investigational Site Number : 2500006
      • Nice, Frankrig, 06200
        • Investigational Site Number : 2500007
      • Paris, Frankrig, 75013
        • Investigational Site Number : 2500002
      • Paris, Frankrig, 75015
        • Investigational Site Number : 2500010
      • Tours, Frankrig, 37044
        • Investigational Site Number : 2500011

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

6 måneder og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Beskrivelse

Inklusionskriterier:

  • Patient med Pompes sygdom, som tidligere har gennemført undersøgelse EFC14028, LTS13769 eller ACT14132 af avalglucosidase alfa undersøgelser i Frankrig.
  • Patienten og/eller dennes forælder/værge er villig og i stand til at give underskrevet informeret samtykke, og patienten, hvis den er under 18 år, er villig til at give samtykke, hvis den skønnes at være i stand til det.
  • Patienten (og patientens juridiske værge, hvis patienten er <18 år) skal have evnen til at overholde den kliniske protokol.
  • Patienten, hvis hun er kvinde og i den fødedygtige alder, skal have et negativt graviditetstestresultat [urin beta-humant choriongonadotropin (β-HCG)] ved indskrivning.
  • Seksuelt aktive kvindelige patienter i den fødedygtige alder og mandlige patienter skal praktisere ægte afholdenhed i overensstemmelse med deres foretrukne og sædvanlige livsstil eller bruge 2 acceptable effektive præventionsmetoder.

Ekskluderingskriterier:

  • Patient med livstruende overfølsomhed (anafylaktisk reaktion) over for et af avalglucosidase alfas hjælpestoffer.
  • Patienten deltager sideløbende i en anden klinisk undersøgelse af forsøgsbehandling.
  • Patienten har klinisk signifikant organisk sygdom (med undtagelse af symptomer relateret til Pompes sygdom), herunder klinisk signifikant kardiovaskulær, hepatobiliær, lunge-, neurologisk eller nyresygdom eller anden medicinsk tilstand, alvorlig interkurrent sygdom eller formildende omstændighed, som i efterforskerens udtalelse, udelukker deltagelse i undersøgelsen eller reducerer potentielt overlevelse.

Ovenstående information er ikke beregnet til at indeholde alle overvejelser, der er relevante for en patients potentielle deltagelse i et klinisk forsøg.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Avalglucosidase alfa
Indgives intravenøst ​​hver anden uge
Medicin: Avalglucosidase alfa (GZ402666)
Lægemiddelform: Sterilt frysetørret pulver Indgivelsesvej: intravenøs (IV) infusion
Andre navne:
  • Nexviadyme®

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Number of participants with adverse events (AE), treatment-emergent adverse events (TEAE), including infusion associated reactions (IAR) and death
Tidsramme: From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Assessment of six-minute walk test (distance in meters and % predicted value) for late-onset Pompe disease (LOPD) and infantile-onset Pompe disease (IOPD) participants
Tidsramme: From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
The primary measurement is the distance in meters walked by the participant on a flat, hard surface in 6 minutes. The distance walked in meters will be recorded and the corresponding percent predicted value will be calculated. The greater the distance (that a participant could walk in 6 minutes), the greater the endurance.
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
Assessment of quick motor function test (QMFT) for LOPD participants
Tidsramme: From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
The QMFT is an observer administered test to evaluate changes in motor function. QMFT comprises of 16 items specifically difficult for participants with Pompe disease. Each item is scored separately on a 5-point ordinal scale (ranged from 0 to 4, higher score indicated better outcome). Total QMFT score is obtained by adding the scores of all items and ranged from 0 (unable to perform motor function tests) to 64 (normal muscle function), higher score represented better outcome.
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
Pulmonary function tests (forced vital capacity [FVC] (% predicted), maximum expiratory pressure/maximum inspiratory pressure) in upright and supine positions for LOPD and IOPD participants
Tidsramme: From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)

FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position, also tested in supine position. Percent of predicted FVC = (actual FVC measurement)/(predicted value of FVC) * 100.

Maximum Inspiratory Pressure (MIP) is a quick and non-invasive test to measure strength of inspiratory muscles, primarily diaphragm, and allows for assessment of ventilatory failure, restrictive lung disease and respiratory muscle strength. MIP refers to how much air pressure force an individual creates by inhaling through the mouth as hard as possible.

Maximum Expiratory Pressure (MEP) is a quick and non-invasive test to measure strength of expiratory muscles, primarily diaphragm, and allows for assessment of ventilatory failure, restrictive lung disease and respiratory muscle strength. MEP is the greater pressure generated during maximal expiration.
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
Quality of life evaluation: 12-item short form health survey (SF-12) for LOPD participants
Tidsramme: From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
SF-12, a 12 item-questionnaire, used to assess health-related quality of life in participants aged >=18 years at screening/baseline. SF-12 consisted of 12 items, which were categorized into eight domains (subscales) of functioning and well-being: physical functioning, role-physical, role emotional, mental health, bodily pain, general health, vitality and social functioning, with each domain score ranged from 0 (poor health) to 100 (better health), higher scores indicated good health condition. These eight domains were further summarized into 2 summary scores, physical component summary (PCS) and mental component summary (MCS). The score range for each of these 2 summary scores was from 0 (poor health) to 100 (better health), higher scores indicated a better health-related quality of life.
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
Quality of life evaluation: Pompe Disease Symptom Scale (PDSS) for LOPD participants
Tidsramme: From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
The 24-hour recall PDSS (V1.1) is a self-administered questionnaires specifically designed to capture the symptoms impacts relevant to patients with LOPD. The PDSS includes 12 questions with responses on a scale from 0 (none) to 10 (as bad as I can imagine) The data from PDSS scale will be analyzed separately and as a composite with PDIS scale.
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
Quality of life evaluation: Pompe Disease Impact Scale (PDIS) for LOPD participants
Tidsramme: From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
The 24-hour recall PDIS (V1.2) is a self-administered questionnaires specifically designed to capture disease impacts relevant to patients with LOPD. The PDIS includes 15 questions with varying scales implemented depending on question type. The data from PDIS scale will be analyzed separately and as a composite with PDSS scale.
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
Pompe Pediatric Evaluation of Disability Inventory (Pompe-PEDI) score for IOPD participants
Tidsramme: From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
The Pompe-PEDI consists of a Functional Skills Scale and a Caregiver Assistance Scale. Both scales have 3 domains: self-care; mobility; and social function. The Mobility Domain was selected to measure change in mobility secondary to changes in muscle strength. The domain consists of 160 mobility items.
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
PedsQL score for IOPD participants
Tidsramme: From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)

The 23item PedsQL Generic Core Scale encompasses 4 subscales including physical, emotional, school, and social functionings. Scores are transformed to a 0-100 scale, higher scores indicate better HRQOL.

Infant scale will not be used since this is a scale for up to 24 months of age and patients are older now than that.
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
Left Ventricular Mass Index (LVMI) Z-score in IOPD participants
Tidsramme: From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
Left Ventricular Mass Index (LVMI) equivalent to mean age specific LVMI plus 2 standard deviations.
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Genzyme, a Sanofi Company

Efterforskere

  • Studieleder: Clinical Sciences & Operations, Sanofi

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

11. juli 2022

Primær færdiggørelse (Anslået)

30. juni 2027

Studieafslutning (Anslået)

30. juni 2027

Datoer for studieregistrering

Først indsendt

16. november 2021

Først indsendt, der opfyldte QC-kriterier

7. december 2021

Først opslået (Faktiske)

20. december 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

4. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • PTA17333
  • 2021-002590-26 (EudraCT nummer)
  • U1111-1266-5434 (Registry Identifier: ICTRP)
  • 2024-514773-22 (Registry Identifier: CTIS)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Kvalificerede forskere kan anmode om adgang til data på patientniveau og relaterede undersøgelsesdokumenter, herunder den kliniske undersøgelsesrapport, undersøgelsesprotokol med eventuelle ændringer, blank case-rapportformular, statistisk analyseplan og datasætspecifikationer. Data på patientniveau vil blive anonymiseret, og undersøgelsesdokumenter vil blive redigeret for at beskytte forsøgsdeltagernes privatliv. Yderligere detaljer om Sanofis kriterier for datadeling, kvalificerede undersøgelser og proces for at anmode om adgang kan findes på: https://vivli.org

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner